Center for Health Policy Studies, School of Public Health, Zhejiang University School of Medicine, Hangzhou 310058, China.
Divisions of Infectious Diseases and Clinical Microbiology, Karolinska Institutet, 17177 Stockholm, Sweden.
Int J Environ Res Public Health. 2020 Mar 10;17(5):1809. doi: 10.3390/ijerph17051809.
Early universal access to antiretroviral treatment (ART) is critical in the control of the HIV epidemic. However, prompt initiation of ART remains problematic in China. This study analyzed the late testing and lag time between HIV diagnosis and initiation of ART from 2004 to 2016 and identified the risk factors for delayed initiation of ART. Data from 16,957 people living with HIV were abstracted from a hospital electronic health record database and a case report database for AIDS prevention and control in Yunnan province. Reasons for delayed initiation of ART were categorized into late testing, defined as CD4 count of < 350 cells/μL at baseline HIV diagnosis, and delayed access, defined as a lag time of > 1 month between the diagnosis and initiation of ART. Binary logistic regression models were used to identify risk factors for late testing and delayed access. The CD4 counts at diagnosis increased from 201 ± 147 cells/μL (mean ± SD) in 2004 to 324 ± 238 cells/μl in 2016 ( = 0.024). The CD4 count was higher for persons < 45 years, unmarried, and men who have sex with men (MSM) (356, 357, and 409 cells/μL, respectively) compared to their peers in 2016 ( < 0.05). The lag time from diagnosis to initiation of ART was significantly reduced from 59.2 months in 2004 to 0.9 months in 2016 ( < 0.05). The shorter lag time over the years was consistent when analysis was stratified by sex, age, marital status, and transmission routes, even though the lag time for people using drugs was longest in 2016 (> 2 months versus 0.82 and 0.72 month of heterosexuals and MSM, respectively). Compared to their peers, married persons (AOR = 0.63, 95%CI: 0.57, 0.69) were less likely to have delayed access to ART, and drugs-using patients (AOR = 3.58, 95%CI: 2.95,4.33) were more likely to have delayed access to ART. Late testing rather than delayed access to ART after a diagnosis remains problematic in China, although improvements have been seen for both parameters from 2004 to 2016. Our data highlight the importance of continued efforts to promote early diagnosis of HIV to prevent transmission, morbidity, and early mortality in HIV infection.
早期普遍获得抗逆转录病毒治疗(ART)是控制 HIV 流行的关键。然而,在中国,迅速开始 ART 治疗仍然存在问题。本研究分析了 2004 年至 2016 年期间 HIV 检测延迟和从 HIV 诊断到开始 ART 之间的时间延迟,并确定了延迟开始 ART 的危险因素。从云南省医院电子健康记录数据库和艾滋病防治病例报告数据库中提取了 16957 名 HIV 感染者的数据。将延迟开始 ART 的原因分为检测延迟,定义为基线 HIV 诊断时 CD4 计数<350 个细胞/μL;以及获得延迟,定义为诊断与开始 ART 之间的时间延迟>1 个月。使用二元逻辑回归模型确定检测延迟和获得延迟的危险因素。诊断时的 CD4 计数从 2004 年的 201±147 个细胞/μL(平均值±标准差)增加到 2016 年的 324±238 个细胞/μL(=0.024)。与同龄人相比,<45 岁、未婚和男男性行为者(MSM)的 CD4 计数更高(分别为 356、357 和 409 个细胞/μL)(<0.05)。从诊断到开始 ART 的时间延迟从 2004 年的 59.2 个月显著减少到 2016 年的 0.9 个月(<0.05)。即使在 2016 年吸毒者的时间延迟最长(>2 个月,而异性恋和 MSM 分别为 0.82 和 0.72 个月),按性别、年龄、婚姻状况和传播途径分层分析时,多年来的时间延迟仍然较短。与同龄人相比,已婚者(AOR=0.63,95%CI:0.57,0.69)不太可能延迟获得 ART 治疗,而吸毒者(AOR=3.58,95%CI:2.95,4.33)更有可能延迟获得 ART 治疗。尽管 2004 年至 2016 年期间这两个参数都有所改善,但中国仍存在 HIV 检测延迟而不是诊断后延迟开始 ART 的问题。我们的数据强调了继续努力促进 HIV 的早期诊断以预防 HIV 感染的传播、发病和早期死亡的重要性。